| Study Protocol Number | Study Title and Description |
|---|---|
| 25-2548 | |
| 25-0466 |
Combining Ziftomenib and Imatinib to Treat Advanced Gastrointestinal Stromal Tumors
This study wants to find a dose of ziftomenib that people with advanced gastrointestinal stromal tumors (CIST) can handle safely when taken with imatinib. We also want to learn how well these two drugs work together. |
| 24-2282 |
A Master Protocol for the Multi-cohort, Open-label, Phase 1/2 Study of DCC-3009 in Participants With Gastrointestinal Stromal Tumors (GIST)
• To evaluate the safety and tolerability of DCC-3009 as monotherapy in participants with advanced GIST. • To determine the recommended dose(s) for expansion in Module A, and if reached, the maximum tolerated dose (MTD) of DCC-3009 as monotherapy. |